You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行》野村預測康方生物(09926.HK)下半年虧轉盈 上調目標價至120.64元
阿思達克 07-18 10:27
野村發表報告,預測康方生物(09926.HK)中期收入按年升42%至14.5億元人民幣,低於市場預期3%。該行料開坦尼及依達方銷售加快,中期收入分別為8億及6億元人民幣。中期經營開支料為13億元人民幣,對比去年上半年及下半年的各12億元人民幣。預期整體中期股東應佔虧損800萬元人民幣,接近收支平衡,對比去年上半年及下半年各錄虧損2.39億及2.76億元人民幣。該行料公司下半年收入19億元人民幣,受開坦尼及依達方銷售推動,以及新推出藥物貢獻,下半年料錄淨利潤2.71億元人民幣。 該行下調對公司今年收入預測9.6%,基於下調對安尼可銷售及協作收益預測,全年淨利潤預測上調97.2%,基於更高毛利率假設。對康方生物目標價由99.66港元上調至120.64港元,維持「中性」評級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account